We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

69 hedge funds and large institutions have $83.9M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

19% more funds holding

Funds holding: 58 → 69 (+11)

10% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $88.1M → $83.9M (-$4.14M)

Holders
69
Holders Change
+11
Holders Change %
+18.97%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
22
Reduced
20
Closed
5
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
-$70K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$18.6M
2
PA
Perceptive Advisors
New York
+$6.89M
3
Millennium Management
Millennium Management
New York
+$1.41M
4
CM
Crestline Management
Texas
+$799K
5
ECM
Endurant Capital Management
California
+$605K

Top Sellers

Rank Fund Capital Flow
1
ASP
Adams Street Partners
Illinois
-$4.27M
2
BlackRock
BlackRock
New York
-$2.47M
3
IHM
Iguana Healthcare Management
New York
-$870K
4
CS
Candriam SCA
Luxembourg
-$218K
5
PP
PDT Partners
New York
-$147K
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
51
Monashee Investment Management
Massachusetts
$58K – – –
DS
52
DRW Securities
Illinois
$56K +$59.8K +13,740 New
GCP
53
GSA Capital Partners
United Kingdom
$56K +$59.9K +13,773 New
Baird Financial Group
54
Baird Financial Group
Wisconsin
$49K – – –
Two Sigma Advisers
55
Two Sigma Advisers
New York
$42K +$44.4K +10,200 New
Bank of Montreal
56
Bank of Montreal
Ontario, Canada
$33K – – –
UBS Group
57
UBS Group
Switzerland
$27K +$4.46K +1,026 +19%
Morgan Stanley
58
Morgan Stanley
New York
$25K -$130K -29,938 -83%
GT
59
Glenmede Trust
Pennsylvania
$13K -$1.3K -300 -8%
Deutsche Bank
60
Deutsche Bank
Germany
$12K +$6.82K +1,568 +111%
BWA
61
Burt Wealth Advisors
Maryland
$8K -$23.9K -5,500 -73%
MAM
62
Meeder Asset Management
Ohio
$4K -$1.09K -250 -19%
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3K -$8.68K -1,994 -72%
CG
64
Cutler Group
California
$3K – – –
FMA
65
FNY Managed Accounts
New York
$2K -$11.7K -2,700 -84%
PMFA
66
Plante Moran Financial Advisors
Michigan
$2K – – –
II
67
Inspire Investing
Idaho
$1K +$1.21K +278 New
ECM
68
Element Capital Management
New York
– -$114K -25,249 Closed
ProShare Advisors
69
ProShare Advisors
Maryland
– -$96K -21,195 Closed
TRCT
70
Tower Research Capital (TRC)
New York
– -$24K -5,250 Closed
Simplex Trading
71
Simplex Trading
Illinois
– -$15K -3,444 Closed
Citigroup
72
Citigroup
New York
– -$6.98K -1,604 -94%
SQA
73
Simon Quick Advisors
New Jersey
– -$3K -561 Closed
Royal Bank of Canada
74
Royal Bank of Canada
Ontario, Canada
– +$252 +58 +414%
1 2
3

OMED Hedge Fund Activity: Q4 2017 in Review

69 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2017, worth a combined $83.9M — down 4.7% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new OMED positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $18.6M. The largest seller was Adams Street Partners, cutting an estimated $4.27M.

  • 69 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2017, up from 58 in Q3 2017.
  • Funds reported $83.9M of OncoMed Pharmaceuticals, Inc. stock for Q4 2017, down 4.7% quarter-over-quarter.
  • 16 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2017 and 5 closed out, a net change of +11 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2017 was BVF Inc, an estimated $18.6M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2017 was Adams Street Partners, an estimated $4.27M sold.

Based on aggregated 13F filings for Q4 2017.